A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
一项随机 II 期临床试验，比较纳武利尤单抗与纳武利尤单抗联合伊匹木单抗治疗 EGFR 突变型非小细胞肺癌的疗效
期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2022.100416
Lai, Gillianne G Y; Yeo, Jia Chi; Jain, Amit; Zhou, Siqin; Pang, Mengyuan; Alvarez, Jacob J S; Sim, Ngak Leng; Tan, Aaron C; Suteja, Lisda; Lim, Tze Wei; Guo, Yu Amanda; Shen, Meixin; Saw, Stephanie P L; Rohatgi, Neha; Yeong, Joe P S; Takano, Angela; Lim, Kiat Hon; Gogna, Apoorva; Too, Chow Wei; Da Zhuang, Kun; Tan, Wan Ling; Kanesvaran, Ravindran; Ng, Quan Sing; Ang, Mei Kim; Rajasekaran, Tanujaa; Wang, Lanying; Toh, Chee Keong; Lim, Wan-Teck; Tam, Wai Leong; Tan, Sze Huey; Skanderup, Anders M J; Tan, Eng-Huat; Tan, Daniel S W
